ubiquitin pathway inhibitors (Proteologics/GSK)

N/A

Report date: 2025/03/20 14:40:37
NME

Base Information

Drug Nameubiquitin pathway inhibitors (Proteologics/GSK)
Drug Alias NameE3 ligase inhibitor (Proteologics/GSK)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionE3 ubiquitin-protein ligase parkin inhibitors
TargetsE3 ubiquitin-protein ligase parkin
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesProteologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProteologics IncGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A